; (II) will promote expedited approval of facilities for the production of such products being built by business enterprises that operate one or more such facilities in the territory of the party; (III) will promote the use of good regulatory practices and streamlined regulatory review and approval processes for the production of such products in the territory of the party; (IV) will eliminate duplicated actions and other barriers to reduce the time for approvals of both facilities and such products; and (V) will expand transparency and cooperation with other parties and their manufacturers, working collaboratively, to ensure regulatory processes are streamlined and harmonized among other parties to the maximum extent possible. (iii) To prohibit export restraints against parties to the agreement, particularly in the event of a declared emergency. (iv) With respect to use of subsidies— (I) to encourage the coordinated provision of those types of subsidies that are classified under World Trade Organization rules as non-prohibited , such as subsidies that are not contingent on exports or import-substitution, to incentivize manufacturing of such products, including the provision of grants, loans, tax incentives, and guaranteed price and volume contracts; (II) to explicitly permit, among parties to the agreement, the use of production subsidies to build pharmaceutical manufacturing capacity; (III) to affirm that subsidies provided by parties are not intended to be used primarily for export or to distort trade; (IV) to affirm parties’ commitments under the Antidumping Agreement and the Agreement on Subsidies and Countervailing Measures, including the recognition that ‘dumping, by which products of one country are introduced into the commerce of another country at less than the normal value of the products, is to be condemned if it causes or threatens material injury to an established industry in the territory of a contracting party or materially retards the establishment of a domestic industry’